Inflammation and the Silent Sequelae of Stroke

Neurotherapeutics

Volumn 13, Issue 4, 2016, Pages 801-810

  Becker, Kyra J ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Depression; Fatigue; Inflammation; Stroke

Indexed keywords

ANTIDEPRESSANT AGENT;

CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); DEPRESSION; FATIGUE; HUMAN; INFLAMMATION; NONHUMAN; POSTSTROKE DEPRESSION; POSTSTROKE FATIGUE; PREVALENCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; ANIMAL; COMPLICATION; DISEASE COURSE; PSYCHOLOGY;

ANIMALS; DEPRESSION; DISEASE PROGRESSION; FATIGUE; HUMANS; INFLAMMATION; STROKE;

EID: 84975317311     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-016-0451-5     Document Type: Review

References (130)

1. Mozaffarian, D., E.J. Benjamin, A.S. Go, et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation 2016. 133: p. e38-e360.
2. Gaete, J.M. and J. Bogousslavsky. Post-stroke depression. Expert Rev Neurother 2008. 8: p. 75-92.
3. Staub, F. and J. Bogousslavsky. Post-stroke depression or fatigue. Eur Neurol 2001. 45: p. 3-5.
4. Ayerbe, L., S. Ayis, C.D. Wolfe, and A.G. Rudd. Natural history, predictors and outcomes of depression after stroke: systematic review and meta-analysis. Br J Psychiatry 2013. 202: p. 14-21.
5. Appelros, P. Prevalence and predictors of pain and fatigue after stroke: a population-based study. Int J Rehabil Res 2006. 29: p. 329-333.
6. Choi-Kwon, S., S.W. Han, S.U. Kwon, and J.S. Kim. Poststroke fatigue: characteristics and related factors. Cerebrovasc Dis 2005. 19: p. 84-90.
7. Carlsson, G.E., A. Moller, and C. Blomstrand. Consequences of mild stroke in persons <75 years—a 1-year follow-up. Cerebrovasc Dis 2003. 16: p. 383-388.
8. Schepers, V.P., A.M. Visser-Meily, M. Ketelaar, and E. Lindeman. Poststroke fatigue: course and its relation to personal and stroke-related factors. Arch Phys Med Rehabil 2006. 87: p. 184-188.
9. van der Werf, S.P., H.L. van den Broek, H.W. Anten, and G. Bleijenberg. Experience of severe fatigue long after stroke and its relation to depressive symptoms and disease characteristics. Eur Neurol 2001. 45: p. 28-33.
10. Parks, N.E., G.A. Eskes, G.J. Gubitz, et al. Fatigue impact scale demonstrates greater fatigue in younger stroke survivors. Can J Neurol Sci 2012. 39: p. 619-625.
11. Naess, H., L. Lunde, J. Brogger, and U. Waje-Andreassen. Fatigue among stroke patients on long-term follow-up. The Bergen Stroke Study. J Neurol Sci 2011. 312: p. 138-141.
12. Feigin, V.L., S. Barker-Collo, V. Parag, et al.,Prevalence and predictors of 6-month fatigue in patients with ischemic stroke: a population-based stroke incidence study in Auckland, New Zealand, 2002–2003. Stroke 2012. 43: p. 2604-2609.
13. Snaphaan, L., S. van der Werf, and F.E. de Leeuw. Time course and risk factors of post-stroke fatigue: a prospective cohort study. Eur J Neurol 2010. 18: p. 611-617.
14. Choi-Kwon, S., J. Choi, S.U. Kwon, D.W. Kang, and J.S. Kim. Fluoxetine is not effective in the treatment of post-stroke fatigue: a double-blind, placebo-controlled study. Cerebrovasc Dis 2007. 23: p. 103-108.
15. Karaiskos, D., E. Tzavellas, K. Spengos, S. Vassilopoulou, and T. Paparrigopoulos. Duloxetine versus citalopram and sertraline in the treatment of poststroke depression, anxiety, and fatigue. J Neuropsychiatry Clin Neurosci 2012. 24: p. 349-353.
16. Winward, C., C. Sackley, Z. Metha, and P.M. Rothwell. A population-based study of the prevalence of fatigue after transient ischemic attack and minor stroke. Stroke 2009. 40: p. 757-761.
17. Paolucci, S., C. Gandolfo, L. Provinciali, R. Torta, and V. Toso. The Italian multicenter observational study on post-stroke depression (DESTRO). J Neurol 2006. 253: p. 556-562.
18. Schwab-Malek, S., B. Vatankhah, U. Bogdahn, M. Horn, and H.J. Audebert. Depressive symptoms and quality of life after thrombolysis in stroke: the TEMPiS study. J Neurol 2010. 257: p. 1848-1854.
19. Shi, Y.Z., Y.T. Xiang, Y. Yang, et al. Depression after minor stroke: the association with disability and quality of life - a 1-year follow-up study. Int J Geriatr Psychiatry 2016;31:421-427.
20. Pompili, M., P. Venturini, D.A. Lamis, et al. Suicide in stroke survivors: epidemiology and prevention. Drugs Aging 2015. 32: p. 21-29.
21. Dou, J., J. Tang, C.H. Lu, E.S. Jiang, and P.X. Wang. A study of suicidal ideation in acute ischemic stroke patients. Health Qual Life Outcomes 2015. 13: p. 7.
22. Sibolt, G., S. Curtze, S. Melkas, et al. Post-stroke depression and depression-executive dysfunction syndrome are associated with recurrence of ischaemic stroke. Cerebrovasc Dis 2013. 36: p. 336-343.
23. Morley, W., K. Jackson, and G.E. Mead. Post-stroke fatigue: an important yet neglected symptom. Age Ageing 2005. 34: p. 313.
24. Bendz, M. The first year of rehabilitation after a stroke—from two perspectives. Scand J Caring Sci 2003. 17: p. 215-222.
25. Glader, E.L., B. Stegmayr, and K. Asplund. Poststroke fatigue: a 2-year follow-up study of stroke patients in Sweden. Stroke 2002. 33: p. 1327-1333.
26. Naess, H., L. Lunde, and J. Brogger. The effects of fatigue, pain, and depression on quality of life in ischemic stroke patients: the Bergen Stroke Study. Vasc Health Risk Manag 2012. 8: p. 407-413.
27. Mead, G.E., C. Graham, P. Dorman, et al. Fatigue after stroke: baseline predictors and influence on survival. Analysis of data from UK patients recruited in the International Stroke Trial. PLoS One 2011. 6: p. e16988.
28. Naess, H., H.I. Nyland, L. Thomassen, J. Aarseth, and K.M. Myhr. Fatigue at long-term follow-up in young adults with cerebral infarction. Cerebrovasc Dis 2005. 20: p. 245-250.
29. Roding, J., B. Lindstrom, J. Malm, and A. Ohman. Frustrated and invisible—younger stroke patients’ experiences of the rehabilitation process. Disabil Rehabil 2003. 25: p. 867-874.
30. Andersen, G., D. Christensen, M. Kirkevold, and S.P. Johnsen. Post-stroke fatigue and return to work: a 2-year follow-up. Acta Neurol Scand 2012. 125: p. 248-253.
31. Kouwenhoven, S.E., M. Kirkevold, K. Engedal, and H.S. Kim. Depression in acute stroke: prevalence, dominant symptoms and associated factors. A systematic literature review. Disabil Rehabil 2011. 33: p. 539-556.
32. Meader, N., T. Moe-Byrne, A. Llewellyn, and A.J. Mitchell. Screening for poststroke major depression: a meta-analysis of diagnostic validity studies. J Neurol Neurosurg Psychiatry 2014;85:198-206.
33. Mead, G., J. Lynch, C. Greig, et al. Evaluation of fatigue scales in stroke patients. Stroke 2007. 38: p. 2090-2095.
34. Lynch, J., G. Mead, C. Greig, et al. Fatigue after stroke: the development and evaluation of a case definition. J Psychosom Res 2007. 63: p. 539-544.
35. Townend, B.S., S. Whyte, T. Desborough, et al. Longitudinal prevalence and determinants of early mood disorder post-stroke. J Clin Neurosci 2007. 14: p. 429-434.
36. White, J.H., J. Attia, J. Sturm, G. Carter, and P. Magin. Predictors of depression and anxiety in community dwelling stroke survivors: a cohort study. Disabil Rehabil 2014. 36: p. 1975-1982.
37. Fu, X., S.M. Zunich, J.C. O’Connor, et al. Central administration of lipopolysaccharide induces depressive-like behavior in vivo and activates brain indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures. J Neuroinflammation 2010. 7: p. 43.
38. Gibney, S.M., B. McGuinness, C. Prendergast, A. Harkin, and T.J. Connor. Poly I:C-induced activation of the immune response is accompanied by depression and anxiety-like behaviours, kynurenine pathway activation and reduced BDNF expression. Brain Behav Immun 2013. 28: p. 170-181.
39. Gunaratne, P., A.R. Lloyd, and U. Vollmer-Conna. Mood disturbance after infection. Aust N Z J Psychiatry 2013. 47: p. 1152-1164.
40. Ford, D.E. and T.P. Erlinger, Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2004. 164: p. 1010-1014.
41. Udina, M., P. Castellvi, J. Moreno-Espana, et al. Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry 2012. 73: p. 1128-1138.
42. Harboe, E., A.B. Tjensvoll, H.K. Vefring, et al. Fatigue in primary Sjogren’s syndrome—a link to sickness behaviour in animals? Brain Behav Immun 2009. 23: p. 1104-1108.
43. Newton, J.L. Fatigue in primary biliary cirrhosis. Clin Liver Dis 2008. 12: p. 367-383; ix.
44. Krupp, L.B. and C. Christodoulou. Fatigue in multiple sclerosis. Curr Neurol Neurosci Rep 2001. 1: p. 294-298.
45. Ramsey-Goldman, R. and N. Rothrock, Fatigue in systemic lupus erythematosus and rheumatoid arthritis. PM R 2010. 2: p. 384-392.
46. Abbas, G., R.A. Jorgensen, and K.D. Lindor. Fatigue in primary biliary cirrhosis. Nat Rev Gastroenterol Hepatol 2010. 7: p. 313-319.
47. Harrison, N.A., L. Brydon, C. Walker, et al. Neural origins of human sickness in interoceptive responses to inflammation. Biol Psychiatry 2009. 66: p. 415-422.
48. Dantzer, R. and K.W. Kelley. Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun 2007;21:153-160.
49. Tate, J., T. Olencki, J. Finke, et al. Phase I trial of simultaneously administered GM-CSF and IL-6 in patients with renal-cell carcinoma: clinical and laboratory effects. Ann Oncol 2001. 12: p. 655-659.
50. Norheim, K.B., E. Harboe, L.G. Goransson, and R. Omdal. Interleukin-1 inhibition and fatigue in primary Sjogren’s syndrome--a double blind, randomised clinical trial. PLoS One 2012. 7: p. e30123.
51. Tookman, A.J., C.L. Jones, M. Dewitte, and P.J. Lodge. Fatigue in patients with advanced cancer: a pilot study of an intervention with infliximab. Support Care Cancer 2008;16:1131-1140.
52. Baranauskaite, A., H. Raffayova, N.V. Kungurov, et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis 2012. 71: p. 541-548.
53. Matsuyama, M., T. Suzuki, H. Tsuboi, et al. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman’s disease. Intern Med 2007. 46: p. 771-774.
54. 54. Strand, V., G.R. Burmester, S. Ogale, et al. Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study. Rheumatology (Oxford) 2012. 51: p. 1860-1869.
55. Burmester, G.R., E. Feist, H. Kellner, et al. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis 2011. 70: p. 755-759.
56. Pascoe, M.C., S.G. Crewther, L.M. Carey, and D.P. Crewther. Inflammation and depression: why poststroke depression may be the norm and not the exception. Int J Stroke 2011. 6: p. 128-135.
57. Yang, R.R., B.C. Lu, T. Li, et al. The relationship between high-sensitivity C-reactive protein at admission and post stroke depression: a 6-month follow-up study. Int J Geriatr Psychiatry 2016. 31: p. 231-239.
58. Zhu, L., B. Han, L. Wang, et al. The association between serum ferritin levels and post-stroke depression. J Affect Disord 2016. 190: p. 98-102.
59. Tang, C.Z., Y.L. Zhang, W.S. Wang, W.G. Li, and J.P. Shi. Elevated serum levels of neopterin at admission predicts depression after acute ischemic stroke: a 6-month follow-up study. Mol Neurobiol 2016;53:3194-3204.
60. Jimenez, I., T. Sobrino, M. Rodriguez-Yanez, et al. High serum levels of leptin are associated with post-stroke depression. Psychol Med 2009. 39: p. 1201-1209.
61. Han, B., Y. Lyu, H. Sun, Y. Wei, and J. He. Low serum levels of vitamin D are associated with post-stroke depression. Eur J Neurol 2015. 22: p. 1269-1274.
62. Cheng, S.Y., Y.D. Zhao, J. Li, et al. Plasma levels of glutamate during stroke is associated with development of post-stroke depression. Psychoneuroendocrinology 2014. 47: p. 126-135.
63. Sulkowski, G., B. Dabrowska-Bouta, M. Chalimoniuk, and L. Struzynska. Effects of antagonists of glutamate receptors on pro-inflammatory cytokines in the brain cortex of rats subjected to experimental autoimmune encephalomyelitis. J Neuroimmunol 2013. 261: p. 67-76.
64. Bolton, C. and C. Paul, Glutamate receptors in neuroinflammatory demyelinating disease. Mediators Inflamm 2006. 2006: p. 93684.
65. Litzelman, K. and M. Verma. Epigenetic regulation in biopsychosocial pathways. Methods Mol Biol, 2015. 1238: p. 549-567.
66. Verma, R., B.D. Friedler, N.M. Harris, and L.D. McCullough. Pair housing reverses post-stroke depressive behavior in mice. Behav Brain Res 2014. 269: p. 155-163.
67. Ormstad, H., H.C. Aass, K.F. Amthor, N. Lund-Sorensen, and L. Sandvik, Serum cytokine and glucose levels as predictors of poststroke fatigue in acute ischemic stroke patients. J Neurol 2011. 258: p. 670-676.
68. Ormstad, H., H.C. Aass, K.F. Amthor, N. Lund-Sorensen, and L. Sandvik. Serum levels of cytokines, glucose, and hemoglobin as possible predictors of poststroke depression, and association with poststroke fatigue. Int J Neurosci 2012. 122: p. 682-690.
69. McKechnie, F., S. Lewis, and G. Mead. A pilot observational study of the association between fatigue after stroke and C-reactive protein. J R Coll Physicians Edinb 2010. 40: p. 9-12.
70. Wu, S., F. Duncan, N.H. Anderson, et al. Exploratory cohort study of associations between serum C-reactive protein and fatigue after stroke. PLoS One 2015. 10: p. e0143784.
71. Michielsen, H.J., J. De Vries, and G.L. Van Heck. Psychometric qualities of a brief self-rated fatigue measure: The Fatigue Assessment Scale. J Psychosom Res 2003. 54: p. 345-352.
72. Michielsen, H.J., M. Drent, T. Peros-Golubicic, and J. De Vries. Fatigue is associated with quality of life in sarcoidosis patients. Chest 2006. 130: p. 989-994.
73. Becker, K., R. Kohen, R. Lee, et al. Poststroke fatigue: hints to a biological mechanism. J Stroke Cerebrovasc Dis 2015. 24: p. 618-621.
74. Reiner, A.P., M.M. Wurfel, L.A. Lange, et al. Polymorphisms of the IL1-receptor antagonist gene (IL1RN) are associated with multiple markers of systemic inflammation. Arterioscler Thromb Vasc Biol 2008. 28: p. 1407-1412.
75. Rafiq, S., K. Stevens, A.J. Hurst, et al. Common genetic variation in the gene encoding interleukin-1-receptor antagonist (IL-1RA) is associated with altered circulating IL-1RA levels. Genes Immun 2007. 8: p. 344-351.
76. Hoffman, P.M., J.M. Powers, M.J. Weise, and S.W. Brostoff. Experimental allergic neuritis. I. Rat strain differences in the response to bovine myelin antigens. Brain Res 1980. 195: p. 355-362.
77. Kunze, A., D. Zierath, O. Drogomiretskiy, and K. Becker. Strain differences in fatigue and depression after experimental stroke. Transl Stroke Res 2014;5:604-611.
78. Ronnback, L. and E. Hansson. On the potential role of glutamate transport in mental fatigue. J Neuroinflammation 2004. 1: p. 22.
79. Syed, A.B., L.M. Castell, A. Ng, C. Winward, and P.M. Rothwell. Plasma glutamate levels predict fatigue after TIA and minor stroke. Cerebrovasc Dis 2007. 23: p. 117.
80. McNally, L., Z. Bhagwagar, and J. Hannestad. Inflammation, glutamate, and glia in depression: a literature review. CNS Spectr 2008. 13: p. 501-510.
81. Fogal, B. and S.J. Hewett, Interleukin-1beta: a bridge between inflammation and excitotoxicity? J Neurochem 2008. 106: p. 1-23.
82. Vesce, S., D. Rossi, L. Brambilla, and A. Volterra. Glutamate release from astrocytes in physiological conditions and in neurodegenerative disorders characterized by neuroinflammation. Int Rev Neurobiol 2007. 82: p. 57-71.
83. Miller, A.H., S. Ancoli-Israel, J.E. Bower, L. Capuron, and M.R. Irwin. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol 2008. 26: p. 971-982.
84. Katafuchi, T., T. Kondo, S. Take, and M. Yoshimura. Brain cytokines and the 5-HT system during poly I:C-induced fatigue. Ann N Y Acad Sci 2006. 1088: p. 230-237.
85. Hopkins, S.J. Central nervous system recognition of peripheral inflammation: a neural, hormonal collaboration. Acta Biomed 2007. 78(Suppl. 1): p. 231-247.
86. Leonard, B.E. and A. Myint, Inflammation and depression: is there a causal connection with dementia? Neurotox Res 2006. 10: p. 149-160.
87. Wichers, M. and M. Maes, The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol 2002. 5: p. 375-388.
88. Jager, A., S. Sleijfer, and C.C. van der Rijt, The pathogenesis of cancer related fatigue: could increased activity of pro-inflammatory cytokines be the common denominator? Eur J Cancer 2008. 44: p. 175-181.
89. Walker, F.R. A critical review of the mechanism of action for the selective serotonin reuptake inhibitors: do these drugs possess anti-inflammatory properties and how relevant is this in the treatment of depression? Neuropharmacology 2013. 67: p. 304-317.
90. Chavda, N., N.D. Kantharia, and Jaykaran, Effects of fluoxetine and escitalopram on C-reactive protein in patients of depression. J Pharmacol Pharmacother 2011. 2: p. 11-16.
91. Dong, C., J.C. Zhang, W. Yao, et al. Effects of escitalopram, R-citalopram, and reboxetine on serum levels of tumor necrosis factor-alpha, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration. Pharmacol Biochem Behav 2016. 144: p. 7-12.
92. Kohler, O., M.E. Benros, M. Nordentoft, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 2014. 71: p. 1381-1391.
93. Glaus, J., C.L. Vandeleur, A.M. Lasserre, et al. Aspirin and statin use and the subsequent development of depression in men and women: results from a longitudinal population-based study. J Affect Disord 2015. 182: p. 126-131.
94. Weinberger, J.F., C.L. Raison, D.B. Rye, et al. Inhibition of tumor necrosis factor improves sleep continuity in patients with treatment resistant depression and high inflammation. Brain Behav Immun 2015. 47: p. 193-200.
95. Raison, C.L., R.E. Rutherford, B.J. Woolwine, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013. 70: p. 31-41.
96. Taylor, D., A. Sparshatt, S. Varma, and O. Olofinjana. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ 2014. 348: p. g1888.
97. Guaiana, G., S. Gupta, D. Chiodo, et al. Agomelatine versus other antidepressive agents for major depression. Cochrane Database Syst Rev, 2013. 12: p. CD008851.
98. Radogna, F., M. Diederich, and L. Ghibelli. Melatonin: a pleiotropic molecule regulating inflammation. Biochem Pharmacol 2010. 80: p. 1844-1852.
99. Pavlov, V.A. and K.J. Tracey. Neural circuitry and immunity. Immunol Res 2015. 63: p. 38-57.
100. Lancaster, G.I. and M.A. Febbraio. The immunomodulating role of exercise in metabolic disease. Trends Immunol 2014. 35: p. 262-269.
101. Nimmo, M.A., M. Leggate, J.L. Viana, and J.A. King. The effect of physical activity on mediators of inflammation. Diabetes Obes Metab 2013. 15(Suppl. 3): p. 51-60.
102. Rimer, J., K. Dwan, D.A. Lawlor, et al. Exercise for depression. Cochrane Database Syst Rev 2012. 7: p. CD004366.
103. Fruehwald, S., E. Gatterbauer, P. Rehak, and U. Baumhackl. Early fluoxetine treatment of post-stroke depression--a three-month double-blind placebo-controlled study with an open-label long-term follow up. J Neurol 2003. 250: p. 347-351.
104. Kucukalic, A., A. Bravo-Mehmedbasic, A.D. Kulenovic, and E. Suljic-Mehmedika. Venlafaxine efficacy and tolerability in the treatment of post-stroke depression. Psychiatr Danub 2007. 19: p. 56-60.
105. Chollet, F., J. Tardy, J.F. Albucher, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol 2011. 10: p. 123-130.
106. Dwyer Hollender, K., Screening, diagnosis, and treatment of post-stroke depression. J Neurosci Nurs 2014. 46: p. 135-141.
107. Esposito, E. and S. Cuzzocrea, Antiinflammatory activity of melatonin in central nervous system. Curr Neuropharmacol 2010. 8: p. 228-242.
108. Lee, M.Y., Y.H. Kuan, H.Y. Chen, et al. Intravenous administration of melatonin reduces the intracerebral cellular inflammatory response following transient focal cerebral ischemia in rats. J Pineal Res 2007. 42: p. 297-309.
109. Zou, L.Y., S.R. Liu, G. Li, L. Huang, and E.S. Yang, Melatonin reduced volume of cerebral infarct induced by photothrombosis in wild-type mice, not in Cyclooxygenase-1 gene knockout mice. Conf Proc IEEE Eng Med Biol Soc 2004. 7: p. 4748-4750.
110. Hu, Y., H. Xing, X. Dong, et al. Pioglitazone is an effective treatment for patients with post-stroke depression combined with type 2 diabetes mellitus. Exp Ther Med 2015. 10: p. 1109-1114.
111. Wahli, W. and L. Michalik, PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol Metab 2012. 23: p. 351-363.
112. Gillespie, W., N. Tyagi, and S.C. Tyagi, Role of PPARgamma, a nuclear hormone receptor in neuroprotection. Indian J Biochem Biophys 2011. 48: p. 73-81.
113. Kernan, W.N., C.M. Viscoli, K.L. Furie, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 2016;374:1321-1331.
114. Smith, P.S. and M. Thompson. Treadmill training post stroke: are there any secondary benefits? A pilot study. Clin Rehabil 2008. 22: p. 997-1002.
115. Eng, J.J. and B. Reime. Exercise for depressive symptoms in stroke patients: a systematic review and meta-analysis. Clin Rehabil 2014. 28: p. 731-739.
116. Hughes, S. (2016) Could MS Drug Have a Role in Acute Stroke? Medscape Medical News.
117. Patejdl, R., I.K. Penner, T.K. Noack, and U.K. Zettl. Multiple sclerosis and fatigue: a review on the contribution of inflammation and immune-mediated neurodegeneration. Autoimmun Rev 2016. 15: p. 210-220.
118. Mucke, M., H. Cuhls, V. Peuckmann-Post, et al. Pharmacological treatments for fatigue associated with palliative care. Cochrane Database Syst Rev 2015. 5: p. CD006788.
119. Heine, M., I. van de Port, M.B. Rietberg, E.E. van Wegen, and G. Kwakkel. Exercise therapy for fatigue in multiple sclerosis. Cochrane Database Syst Rev 2015. 9: p. CD009956.
120. Shaygannejad, V., M. Janghorbani, F. Ashtari, and H. Zakeri. Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. Neurol Res 2012. 34: p. 854-858.
121. Wingerchuk, D.M., E.E. Benarroch, P.C. O’Brien, et al. A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology 2005. 64: p. 1267-1269.
122. McGeough, E., A. Pollock, L.N. Smith, et al. Interventions for post-stroke fatigue. Cochrane Database Syst Rev 2009: p. CD007030.
123. Poulsen, M.B., B. Damgaard, B. Zerahn, K. Overgaard, and R.S. Rasmussen. Modafinil may alleviate poststroke fatigue: a randomized, placebo-controlled, double-blinded trial. Stroke 2015. 46: p. 3470-3477.
124. Zedlitz, A.M., T.C. Rietveld, A.C. Geurts, and L. Fasotti. Cognitive and graded activity training can alleviate persistent fatigue after stroke: a randomized, controlled trial. Stroke 2012. 43: p. 1046-1051.
125. Adamopoulos, S., J. Parissis, D. Karatzas, et al. Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure. J Am Coll Cardiol 2002. 39: p. 653-663.
126. Pedersen, B.K. The anti-inflammatory effect of exercise: its role in diabetes and cardiovascular disease control. Essays Biochem 2006. 42: p. 105-117.
127. Kohut, M.L., D.A. McCann, D.W. Russell, et al. Aerobic exercise, but not flexibility/resistance exercise, reduces serum IL-18, CRP, and IL-6 independent of beta-blockers, BMI, and psychosocial factors in older adults. Brain Behav Immun 2006. 20: p. 201-209.
128. Gao, X.R., C.M. Adhikari, L.Y. Peng, et al. Efficacy of different doses of aspirin in decreasing blood levels of inflammatory markers in patients with cardiovascular metabolic syndrome. J Pharm Pharmacol 2009. 61: p. 1505-1510.
129. Ikonomidis, I., F. Andreotti, E. Economou, et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999. 100: p. 793-798.
130. Yildiz, M., B. Tettenborn, and N. Putzki. Multiple sclerosis-associated fatigue during disease-modifying treatment with natalizumab, interferon-beta and glatiramer acetate. Eur Neurol 2011. 65: p. 231-232.